Amgen is providing refunds for 340B overcharges for four NDCs of its top-selling drug Enbrel during 2016 and 2017.

Amgen and GSK Announce Refunds for 340B Overcharges

Drug manufacturer Amgen is providing refunds for overcharges during varying periods over three years on some of its top selling drugs including Enbrel ($4.8 billion in U.S. sales in 2020), Neulasta ($2 billion), Kyprolis ($710 million), Aranesp ($629 million), Epogen ($598 million), Repatha ($459 million), and Blincyto ($231 million).

GlaxoSmithKline has similarly announced it is providing refunds for 340B overcharges during Q2 2020 on six drugs (a total of 16 NDCs)—the inhaled drugs Anoro Ellipta, Arnuity Ellipta, Breo Ellipta, Incruse Ellipta, and Trelegy Ellipta and the injectable diabetes type 2 medicine Tanzeum.

Drug manufacturers Amgen and GlaxoSmithKline have announced refunds for 340B overcharges.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report